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Background: Self-aggregation of -amyloid plays an important role in the pathogenesis of Alzheimer disease.
Results: Small molecule inhibitors of -amyloid fibril formation reduce -amyloid mediated cell toxicity.
Conclusion: Rational design led to the successful development of small molecule inhibitors of -amyloid oligomerization and
toxicity.
Significance: Small molecules targeting -amyloid misfolding may provide new treatments for Alzheimer disease.
Increasing evidence implicatesApeptides self-assembly and
fibril formation as crucial events in the pathogenesis of
Alzheimer disease. Thus, inhibiting A aggregation, among
others, has emerged as a potential therapeutic intervention for
this disorder. Herein, we employed 3-aminopyrazole as a key
fragment in our design of non-dye compounds capable of inter-
acting with A42 via a donor-acceptor-donor hydrogen bond
pattern complementary to that of the -sheet conformation of
A42. The initial design of the compounds was based on con-
necting two 3-aminopyrazole moieties via a linker to identify
suitable scaffoldmolecules. Additional aryl substitutions on the
two 3-aminopyrazole moieties were also explored to enhance
- stacking/hydrophobic interactions with amino acids of
A42. The efficacy of these compounds on inhibiting A fibril
formation and toxicity in vitrowas assessed using a combination
of biophysical techniques and viability assays. Using structure
activity relationship data from the in vitro assays, we identified
compounds capable of preventing pathological self-assembly of
A42 leading to decreased cell toxicity.
Alzheimer disease (AD)2 is the most common age-related
neurodegenerative disorder affecting nearly 25million patients
(1). It is characterized by progressive cognitive decline and
eventually a debilitating dementia (2). Currently available phar-
macologic interventions are limited to compounds enhancing
cholinergic function (acetylcholinesterase inhibitors) or acting
as N-methyl-D-aspartic acid receptor antagonist, but these
drugs only provide symptomatic relief without halting the pro-
gression of the disease (3–5). Thus, there is an enormous med-
ical need for novel disease-modifying therapies that target the
underlying neuropathological mechanisms involved in the
development of AD.
The two pathological hallmarks of AD are senile amyloid-
(A) plaques (6) and neurofibrillary tanglesmade of aggregated
Tau (7). According to the amyloid cascade hypothesis, the
aggregation of A is the primary cause of the disease (8–11).
Thus, removal of toxic amyloid deposits is a central therapeutic
aim in AD (12). The A1–42 peptide (A42) is the more neu-
rotoxic form of A, as A42 has more pronounced oligomeri-
zation and aggregation properties (13–15).
The majority of studies on A toxicity suggest that low
molecular weight soluble oligomers or high molecular weight
prefibrillar intermediates account for its neurotoxicity (16–20),
synapse loss, and cognitive impairment (21). A fibrils and high
molecular weight oligomers are rich in -sheet structures,
whereas low molecular weight oligomers (dimers, trimers,
tetramers) do not adopt stable secondary structures. The dif-
ferent transient A speciesmost likely exist in equilibriumwith
each other (22–23).
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The amyloid cascade hypothesis offers several strategies for
therapeutic intervention, including inhibition of A produc-
tion (- and/or -secretase inhibitors) or inhibition of A
aggregation and toxicity. Preventing A aggregation is thera-
peutically attractive because this might be an exclusively path-
ological process and would not interfere with the physiological
function of the amyloid precursor protein (20).
Thus, a potential method of treating AD is to administer
small molecules capable of preventing A oligomerization,
fibrillization, and/or plaque formation (24–26). Themajority of
non-peptidic anti A-aggregation inhibitors identified by in
vitro screening are metal chelators (27), dyes (28, 29), and poly-
phenolic natural products (30–34).
An alternative approach is based on a rational design utiliz-
ing acylated 3-aminopyrazoles with a donor-acceptor-donor
hydrogen bond pattern complementary to that of the-sheet of
A42 (35, 36) (Fig. 1A). These compounds bearing 3-amino-
pyrazoles are either dimeric compounds, where the 3-amino-
pyrazolemoieties are connected by a rigid oxalyl-linker, or olig-
omeric compounds, where the 3-aminopyrazole moieties are
directly linked to each other by amide bonds (35, 36).
Highly ordered -stacking interactions between aromatic
ring systems play important roles in -sheet formation and
assembly of complex biological and chemical supramolecular
structures (37). Previous studies suggested that the anti-aggre-
gation properties of polyphenols result from their ability to
interfere with -stacking interactions between aromatic side
chains in amyloid (38). Thus, we hypothesized that in addition
to the already existing donor-acceptor-donor contacts, aro-
matic substituents attached at the 4- or 5-position of the
3-aminopyrazole ring should increase the anti-aggregation
potency of our compounds. Herein, we demonstrate that ratio-
nally designed small molecules inhibit A oligomerization,
fibril formation, and protect against A-induced toxicity.
EXPERIMENTAL PROCEDURES
Compound Synthesis—The synthesis of compounds 1-14
(Fig. 1B) from commercially available starting materials is
described in supplemental Fig. S5–S9.
Thioflavin T (ThT) Fluorescence Assays—A42 lyophilized
powder (Bachem) was reconstituted in hexafluoroisopropanol
to 1mM. The peptide solutionwas sonicated for 15min at room
temperature and agitated overnight, and aliquots were made
into non-siliconizedmicrocentrifuge tubes. The hexafluoroiso-
propanol was then evaporated under a stream of argon. The
resulting peptide film was dried under a vacuum for 10 min,
tightly sealed, and stored at80 °C until used.
For the ThT assay, a PBS solution in non-siliconized incuba-
tion tubes was prepared with final concentrations of 330 M
inhibitors, 33 M A42, and 10 M ThT (Sigma). The final
concentration of DMSO was 12.8%. Therefore, the final molar
ratio of test compound toA42was 10:1. A solution containing
A42 and 10 M ThT only was used to measure the maximal
relative fluorescence unit (defined as 100% relative fluores-
cence units). A negative control without A42 defined as 0%
relative fluorescence unit was also prepared for each compound
to exclude compound-derived fluorescence. The assay was run
for 24 h at 37 °C, and the spectrofluorescence (excitation, 440
nm; emission, 485 nm)was read in 6 replicates in black 384-well
assay plates (PerkinElmer Life Sciences) in a microplate reader
(Tecan). The ThT-assay IC50 determination was performed as
described abovewith the exception that the following 7 concen-
trations of test compound were used: 330, 82.5, 20.63, 5.16,
1.29, 0.32, and 0.08 M. The IC50 values were determined from
the percent inhibition of aggregation values obtained at the end
of the measurement. Thereafter these values were plotted
against the log of the inhibitor concentration. By fitting the data
with a sigmoidal function in the Prism software (GraphPad
Software), the IC50 values were obtained.
A42 protofibrils were prepared essentially as described (20,
39). Briefly, 1mg of lyophilized A42 was solubilized in 50l of
100% anhydrous DMSO in a 1.5-ml sterile microtube. Then,
800 l of high purity water was immediately added, and the pH
of the resulting solutionwas adjusted to7.6 by adding 10l of
2 MTris-base, pH 7.6. The solutionwas centrifuged (16,000 g;
4 °C; 10min), and the supernatant was injected into a Superdex
75 column previously equilibrated with 50 ml of 10 mM Tris-
HCl, pH 7.4. A42 monomers were prepared as described
above, except that 1mg of lyophilizedA42was solubilized in 6
M guanidine hydrochloride (1ml), and the solution was directly
injected into the Superdex 75 column (20, 39). A42 was eluted
at a flow rate of 0.5ml/min, and 1-ml fractionswere collected in
1.5-ml sterile microtubes (supplemental Fig. S10). The elution
was monitored at UV absorbance A210, A254, and A280. A42
concentrationwas determined from theA280 using the theoret-
ical molar extinction coefficient 1490 M1cm1 (39, 40). In Jan
et al. (39) we validated the reliability of this method.
A42 monomers and protofibrils (20 M) were separately
co-incubated with the test compounds at the following molar
ratios (A42 test compounds): 1:0.5, 1:1, and 1:2 in 1.5-ml ster-
ile microtubes (500 l/tube, in duplicates). For this purpose,
dilutions of the test compoundswere prepared from stock solu-
tions in 100% anhydrous DMSO in such a manner that each
tube containing A42 monomers or protofibrils received an
identical volume of the test compound stock solutions. As con-
trols, the equal volume of 100% anhydrous DMSO was sepa-
rately added toA42monomers andprotofibrils. For validation
experiments, purified A42 monomers and protofibrils were
co-incubated with selected test compounds at a molar ratio of
1:4 (10 M A42, 40 M compound).
The samples were incubated at 37 °C, and fibril formation
wasmonitored by theThTbinding assay and transmission elec-
tron microscopy (TEM). ThT fluorescence was determined
every 24 h up to 72 h of incubation. For this purpose, 80 l of
A42 monomers or protofibrils with and without test com-
pounds were mixed with 20 l of ThT (100 M) and 10 l of
glycine-NaOH, pH 8.5 (500 mM), in a Nunc 384-well fluores-
cence plate (100l/well). ThT fluorescence of each sample was
measured in anAnalyst AD fluorometer (Molecular Devices) at
excitation and emission wavelengths of 450 and 485 nm,
respectively.
A42 fibrils were prepared as described (20, 39). Briefly, a
concentrated solution (1 mg/ml) of the A42 preparation to
obtain protofibrils, containing monomers, protofibrils, and a
small amount of fibrils, was incubated at 37 °C, pH 7.8, under
mild agitation for 48 h. A42 fibrils (100M) were incubated at
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37 °Cwith eitherDMSO (40M) or the test compounds (40M)
in 1.5-ml sterile microtubes (600 l/tube, in duplicates), and
fibril disaggregation was monitored by the ThT binding assay
and TEM. ThT fluorescence was determined at 0 and 48 h
before adding the test compounds to monitor A42 fibril for-
mation. After the addition of DMSO or the test compounds,
ThT fluorescence was determined at 24 and 48 h.
Analysis of Soluble A42 by SDS-PAGE—After 48 h of incu-
bation at 37 °C, A42 samples (monomers or protofibrils) with
or without test compounds were centrifuged (16,000  g, 15
min, 4 °C). In contrast, A42 fibril samples with or without test
compounds were ultracentrifuged (100,000  g, 30 min, 4 °C).
Then, 10–12 l of the supernatant (monomers or protofibrils
or fibrils) wasmixedwith SDS loading buffer (41) and subjected
to electrophoresis on NuPAGE 4–12% Bis-tris SDS gels (Invit-
rogen). The supernatant from A42 fibrils was also filtered
through 0.22-m filters previously equilibrated with 10 mM
Tris-HCl, pH 7.4, by centrifugation (14,000 rpm, 10 min). The
protein bands were visualized by silver staining using a com-
mercial kit (Invitrogen).
TEM—A 5–10-l droplet of sample containing A42 was
deposited on a 200-mesh Formvar-coated TEM grid (EM Sci-
ences) and allowed to settle for 60 s. Then the excess solution
was wicked away by gently applying a piece of blotting paper to
the edge of the grid. Then a 10-l droplet of 2% uranyl acetate
was deposited on the grid and allowed to settle for 60 s. The
excess solution was removed as above. Then the grid was vac-
uum-dried by gently applying the vacuum probe on a grid side.
Image acquisitionwas carried out using a Phillips CM10micro-
scope operated at an acceleration voltage of 80 kV.
Fluorescence Correlation Spectroscopy (FCS)—Measure-
ments were performed using a ConfoCor I (Zeiss, Evotec)
instrument equipped with an argon ion laser. The pinhole
diameter was 40 m. The instrument was calibrated with the
dye rhodamine 6G with a known diffusion coefficient in water
at 20 °C of 2.8106 cm2/s. TheA42 peptidewas labeledN-ter-
minally with the fluorescence dye Oregon green as described
(36). Compounds were tested using preformed aggregates that
were prepared freshly by diluting low concentrated (500 nM)
DMSO-stock solutions of Oregon green-labeled A42 1:1 with
deionizedwater. For eachmeasurement a new aliquot, stored at
70 °C, was thawed and sterile-filtered through a nylon filter
(0.2 m) to remove large aggregates. Final concentration of
Oregon green-labeled A42 peptide in the assay was 5 nM in
PBS and 6% DMSO.
The compoundswere dissolved in 100%anhydrousDMSOat
50-fold concentration of the desired assay concentration, so
that a constant amount of 1 l of ligand stock solution was
always added to the test solution. This latter contained 10-fold
concentrated PBS, water, 8 M mercapto-ethylamine and was
distributed as 48-l aliquots to 12 standard reaction vials. Mer-
captoethylamine was added to the assay mixtures to reduce the
rather high triplett fraction of the dye Oregon green as a so
called triplett quencher (42).
After the calibration of the FCS instrument, the assay was
started by adding 1l ofA42-Oregon green-labeled peptide in
DMSO, and the aggregation process was analyzed over a period
of 5 h. Samples were prepared at least as duplicates. Data eval-
uation was carried out by averaging the fluorescence fluctua-
tions for everywell and counting data points that deviatedmore
than 5-fold from themean fluorescence signal, i.e. every peak at
a Z-score equal or higher than 5 was counted as an A42
aggregate (36). Because the intensity of the fluorescence peaks
is related to the number of dye molecules present in A42
aggregates, not only the number of peaks but also the product of
number and height of peaks was evaluated. The results of every
measurement were normalized to the values measured for the
control samples (36).
Cell Viability Assay—To evaluate cell viability of SH-SY5Y
neuroblastoma cells, a standard 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reduction assay was
employed according to the manufacturer’s instructions
(Promega). Crude A42 was prepared as described previ-
ously (20, 39). Briefly, 1 mg of lyophilized A42 was solubi-
lized in 20 l of 100% anhydrous DMSO in a 1.5-ml sterile
microtube. Then 800 l of high purity water was immedi-
ately added, and the pH of the resulting solution was
adjusted to7.6 by adding 10 l of 2 M Tris base, pH 7.6. The
solution was always freshly prepared and used immediately.
Crude A42 with or without compound was incubated for 30
min in serum-free culture medium complemented with
insulin and then added onto the cells (plated in 96-well-
plates) for 24 h. TheMTT-dye solution was added for the last
3 h of incubation. Then the cells were incubated for 1 h in a
solubilization solution, and the blue formazan product was
measured at 570 nm using 690 nm as a reference wavelength
in a microplate reader (Tecan). The signal was expressed as
percentage of the A570–690 count from the vehicle-treated
cells.
Internalization Assay—To evaluate the internalization of
crude A42, SH-SY5Y cells were plated in 6-well plates at a
density of 5 105 cells/well. Crude A42 (3 M) was preincu-
bated for 1 h with compound (3 M) in a 1:1 molar ratio. The
SH-SY5Y cells were then incubated for 2 h with the crude
A42/compound mixture, washed with ice-cold PBS, tryp-
sinized, and centrifuged in ice-cold PBS at 1500 rpm for 5 min.
The cells were resuspended in 80 l of cell lysis buffer (Cell
Signaling Technology) for 5 min on ice and then briefly soni-
cated. The lysate was centrifuged for 5 min at 14,000  g, and
the protein concentration of supernatants was determined
using a microbicinchoninic acid protein assay kit (Thermo Sci-
entific). Internalized A42 was detected with a human A42
ELISA high sensitivity detection kit (Millipore) following the
manufacturer instructions, and the data were normalized by
the total protein concentration of the samples.
Nuclear Magnetic Resonance Experiments—One-dimen-
sional and two-dimensional NMR experiments were per-
formed at 5 °C on a 700-MHz spectrometer (Bruker) equipped
with a cryogenic probe. Commercially available 15N-labeled
A42 (rPeptide) was solubilized in 100 mMNaOH at a concen-
tration of 2 mg/ml. Compounds were dissolved in deuterated
DMSO at 100 mM concentration. In the titration experiments
the initial sample contained 50 M 15N-labeled A42 in 50 mM
phosphate buffer (pH 7.5, adjusted after the addition of the
labeled peptide and kept constant along the titration). The
titration series contained compounds 6, 7, or 10 in increasing
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compound/peptide ratios up to a ratio of30. At this ratio, the
DMSO concentration was 1.4% (v/v). The reference experi-
ment was conducted using DMSO at 1.4% concentration and
the same pH but without any added compound. Chemical shift
referencing and intensity normalization was performed on the
basis of an internal 4,4-dimethyl-4-silapentane-1-sulfonic acid
reference.
Saturation transfer difference (STD) experiments were con-
ducted at the specified irradiation frequencies, with irradiation
at 60 ppm used as the reference spectrum. The difference
between the saturated and reference spectra (saturated-refer-
ence) is shown as the STD spectra. A saturation block of 5 s and
a recycle delay of 7 s were used for STD experiments. The sam-
ples contained 0.4 mM compound with or without the added
peptide (at compound/peptide ratio of 16:1). The sample with-
out the added peptide did not show any STD effect at the used
frequencies. Two preparations of A42 were used for the STD
experiments; the first was the normally solubilized A42 sup-
posed to be rich of the monomeric A42 peptide, and the sec-
ond was incubated at 37 °C for 24 h (without stirring) to be
enriched in oligomeric species.
RESULTS
Screening for Inhibitors of Fibril Formation Using ThT As-
says—We first investigated the effect of our compounds (Fig.
1B) on the aggregation and fibril formation of A42 by the
mean of different ThT fluorescent assays (43). Because this dye
binds to amyloidogenic cross--sheet structures, ThT assays
arewidely used for the identification and quantification of amy-
loid fibrils and tomonitor fibril formation kinetics (44). For this
purpose a high concentration of ThT was added to A42 fibril-
lization samples in order to be in excess compared with the
number of potential ThT-fibril binding sites (44).
A42 was prepared for the first screening assay as a resus-
pended peptide film containing monomeric and heterogenic
mixtures of low molecular weight A42 oligomers (16 kDa),
as determined byWestern blot and centrifugation (Fig. 2A).We
have shown that such crudeA42 preparations are toxic to cells
(20). The incubation time was 24 h, as preliminary experiments
have shown that within this time the aggregation process was
completed (ThT signal reached a steady state). In general, a com-
pound was considered active in this assay when at least 70% inhi-
FIGURE 1. A, Shown is the structure of the Ampox (N1,N2-bis(5-methyl-1H-pyrazol-3-yl)oxalamide); Ref. 35) compound, the numbering of the pyrazole moiety,
the linker unit, and the possible donor-acceptor-donor interactions of the 3-amino-pyrazole moiety with A42 peptide aggregates having cross--sheet
conformation. B, structures of the small molecule inhibitors 1–14 of A42 fibrillization containing different aromatic substituents at the 4- or 5-position of the
3-aminopyrazole moiety.
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bition of A42 aggregation was observed. The Trimer inhibitor
(36) of A42 aggregationwas used as positive control in this assay
and displayed70% inhibition (data not shown).
Attaching bulky aromatic substituents at the 4-position of
3-aminopyrazole as for compound 1 (Fig. 1B) did not yield an
active compound (Fig. 2A). This may be due to the fact that
the rigid (-C(O)C(O)-) linker prevented additional interac-
tions of the aromatic substituents with A42. The incorpora-
tion of a more flexible (-CH2CH2-) linker in compound 2
increased its activity compared with 1. However, the inhibition
ofA42 aggregationwas still70%, indicating that compounds
with substituents at the 4-position of 3-aminopyrazole were
suboptimal.
By employing a flexible (-CH2CH2-) linker and attaching aro-
matic substituents at the 5-position of the 3-aminopyrazole
ring compounds 3–8, 10, and 13 (Fig. 1B) were obtained. Com-
pounds having strong electron-donating groups (p-OCH3 for
compound 4 or p-N(CH3)2 for compound 7), weak electron-
donating groups (p-CH3 for compound 3 or p-phenyl for com-
pound 8), or strong electron-withdrawing groups (p-Cl for
compound 5 or p-F for compound 6) attached to the 5-phenyl-
substituents, all displayed70% of inhibition of A42 aggrega-
tion in this assay (Fig. 2A). These data, however, showed no
clear preference for the different phenyl substituents at the
5-position of 3-aminopyrazole. Furthermore, compounds 10
and 13 with a non-symmetrical substitution pattern at the
5-position of the 3-aminopyrazole moiety displayed equal
activity. Thus, the heteroaromatic 2-thienyl moiety in com-
pound 10 retained the inhibition of fibrillization activity. How-
ever, compound 9 bearing a heteroaromatic 2-furanyl moiety
displayed a decrease in activity with 70% inhibition of A42
aggregation. Compound 13 containing the flexible (-CH2CH2-)
linker showed superior inhibition of A42 aggregation when
compared with the structurally related compounds 11 and 12
containing a partially reduced (-C(O)CH2-) linker. Compound
14 containing a shorter (-CH2-) linker was inferior to the oth-
erwise identical compound 3 having a (-CH2CH2-) linker.
However, the shorter butmore flexible (-CH2-) linkerwas supe-
rior to the partially reduced (-C(O)CH2-) linker (compare com-
pounds 11, 12, and 14; Fig. 2A). In summary, compounds con-
taining a flexible (-CH2CH2-) linker unit and having an
aromatic substituent attached to the 5-position of 3-amino-
pyrazole (Fig. 1B) demonstrated the strongest inhibition of
A42 fibrillization.
Investigating the Inhibition of Fibril FormationUsing Purified
A42 Monomers and Protofibrils—To elucidate which A42
species interact with our compounds and also to confirm the
screening results obtained with the A42 peptide film, we next
investigated the potency of compounds 1–14 on inhibiting
fibril formation of purified A42 monomers or protofibrils, i.e.
interference with A42 nucleation or elongation. For this pur-
pose A42monomers or A42 protofibrils of defined size were
prepared by size exclusion chromatography (supplemental Fig.
S10) and characterized as previously described (39).
Testing the compounds by incubating them with A42
monomers or protofibrils (A42:compoundmolar ratios of 0.5,
1, and 2; 72-h incubation time) revealed that compounds 3–7,
10, and 13 led to a50% inhibition of fibril maturation starting
fromA42monomers (Fig. 2B), and a A42:compound ratio of
1:2 inhibited the elongation of A42 protofibrils into mature
fibrils (Fig. 2C). At substoichiometric concentrations (0.5molar
FIGURE 2. In vitro screening assays using A42 peptide film (A), A42
monomers (B), and A42 protofibrils (C). A, the concentration of A42
peptide filmwas33M.The test concentration for compounds1–14was330M,
and the incubation time was 24 h. The data are expressed as the percentage
(mean S.D.) of control conditions: A42 aggregationwith DMSOonly. Freshly
prepared A42 peptide film (4 g) was analyzed by SDS-PAGE to confirm the
presence of oligomeric A42 present (a, molecular weightmarker; b, A42 pep-
tide film). B, the concentration of A42monomers was 20M. C, the concentra-
tionofA42protofibrilswas20M.Compounds1–14at10M(1:0.5; 1%DMSO),
20M (1:1; 2%DMSO), and 40M (1:2; 4%DMSO)were co-incubatedwith A42
monomers or protofibrils for 72 h. The data are expressed as the percentage
(mean S.D.) of the ThT fluorescence of the 4%DMSO control.
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ratio), the inhibition of fibril formation was generally weaker
for most of the compounds tested (Fig. 2, B and C).
In contrast, compounds 1, 2, 8, 9, 11, 12, and 14 exhibited
low to moderate activity, i.e. 50% against the fibrillization of
A42 monomers (Fig. 2B) or protofibrils (Fig. 2C). Interest-
ingly, compound 1 appeared to enhance the fibrillization of
monomeric A42 when compared with the control. The data
showed that compounds 1 and 2with an aromaticmoiety at the
4-position of the 3-aminopyrazole moiety were less effective in
inhibiting the fibrillization of both A42monomers and proto-
fibrils when comparedwith compounds 3–7, 10, and 13 having
an aromatic moiety at the 5-position of the 3-aminopyrazole.
Unlike the results obtained with the A42 peptide film, com-
pounds 11 and 12 showed similar inhibition of A42 fibril for-
mation starting from both A42 monomers and protofibrils.
Again, compound 9, having the 2-furanyl moiety, displayed a
weaker effect on inhibition of fibril formation (50%) in both
assays. In contrast to the results obtained with the crude A42
peptide film, compound 8 was less potent when A42 mono-
mers or protofibrils were used, displaying 50% inhibition of
A42 fibril formation.
Taken together, the results from our in vitro screening assays
(Fig. 2,A–C) were in good agreement. Thus, compounds 3, 5, 6,
7, 10, and 13 containing a flexible (-CH2CH2-) linker and dif-
ferent aromatic substituents at the 5-position of 3-aminopyra-
zole displayed potent inhibition of both A42 nucleation and
A42 protofibril elongation.
Validation of Representative Hit Compounds and Elucida-
tion of Their Mode of Action—Compound 1 was selected as a
negative control because it did not show any activity in the
previous in vitro screening assays. In contrast, compounds 5, 6,
7, and 10 displayed good inhibition of A42 aggregation in the
previous screening assays. These compounds were again tested
in the ThT assay using the A42 peptide film preparation to
determine their IC50 values. For compound 1 the IC50 could not
be determined (data not shown). The IC50 values for com-
pounds 5, 6, 7, and 10 were 8.6, 40.5, 7.5, and 29 M, respec-
tively (Fig. 3 and supplemental Fig. S1). In summary, compound
7 displayed the most potent inhibition of A42 fibrillization in
the ThT assay followed by compounds 5, 10, and 6.
To explore in more details the mechanism(s) by which com-
pounds 1, 5, 6, 7, and 10 inhibited the fibrillization of A42, we
investigated their effect on the kinetic of A42 fibril formation
starting with purified A42 monomer preparations. Fibril for-
mation kinetic of A42monomers was studied over a period of
48 h with and without compounds (Fig. 4A) using a ThT read-
out (45). Incubation of A42 monomers in the presence of
compounds 5, 6, 7, and 10 resulted in an initial rise of the ThT
signal after 24 h similar to A42 monomers incubated without
compounds. However, after 48 h the ThT signal was signifi-
cantly lower as comparedwith the control (Fig. 4A). Compound
1 had no effect on A42 monomer fibrillization as the increase
in ThT signal over 48 h was comparable to the DMSO control.
Testing compounds in a fluorescent-based assay has an
inherent risk of readout artifacts. As an example, compounds
with absorption at440nm (the excitationwavelength ofThT)
may quench or interfere with the fluorescence readout (44, 46).
So, we employed an orthogonal, non-fluorescence-based assay
based on the different sedimentation properties of soluble and
aggregated A42. For this, samples were centrifuged, and
supernatants were analyzed for soluble A42 protein (mono-
mers, oligomers, and protofibrils) by SDS-PAGE (Fig. 4B). In
agreement with the ThT data, SDS-PAGE analysis after 48 h of
incubation at 37 °C revealed a substantial reduction in the con-
tent of soluble A42 in the control and compound 1-treated
sample, suggesting that almost all soluble A42 was converted
into insoluble fibrils. This was also in agreement with the TEM
images (Fig. 4C) of the control and compound 1-treated sample
showing bundles of extensive mature fibrils.
The samples treated with compounds 5, 6, 7, and 10 showed
that significant amounts of soluble A42 (monomers and
protofibrils) remained in the supernatant, which was also in
agreement with the ThT data. This suggests an interaction of
compounds 5, 6, 7, and 10 with A42 oligomers/protofibrils
and subsequent prevention of their maturation into insoluble
species. In agreement with the ThT and SDS-PAGE data, sam-
ples containing compounds 5, 6, 7, and 10 did not showmature
fibrils in TEM but resulted in the formation of non-fibrillar
clusters of curvilinear protofibrils (Fig. 4C). The curvilinear,
irregular morphology of A42 protofibrils is quite different
from mature amyloid fibrils (47, 48).
Thus, compounds 5, 6, 7, and 10 did not sequester A42
monomers and, hence, did not interfere with A42 monomer
oligomerization and seed formation. Instead, compounds 5, 6,
7, and 10 appeared to target prefibrillar A42 oligomers to
prevent fibrillization.
Next, we performed a kinetic analysis of the fibrillization of
preformedA42 protofibrils to probe the ability of compounds
1, 5, 6, 7, and 10 to interact with these structures. In the pres-
ence of DMSO alone, A42 protofibrils displayed a ThT signal
already at 0 h, confirming the presence of oligomeric aggregates
with high -sheet content (Fig. 5A). Then, over the first 24 h,
the ThT fluorescence increased with time, consistent with the
conversion of protofibrils into mature fibrils. The fibrillization
process then slowed down over the next 24 h of incubation
because the conversion of protofibrils into mature fibrils
requires the presence of small, soluble A42 species. The rise of
the ThT signal for samples treated with compound 1 suggested
FIGURE 3. IC50 determination assay using A42 peptide film. The concen-
tration of A42 peptide film was 33 M. The test concentration for com-
pounds 5, 6, 7, and 10were 330, 82.5, 20.63, 5.16, 1.29, 0.32, and 0.08Mwith
an incubation time of 24 h. The IC50 values were determined from the fluo-
rescence values obtained. TheThT IC50-data are expressedas themean S.D.
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a somehow promoted A42 protofibril fibrillization process
(Fig. 5A). This is in agreement with the TEM image (Fig. 5C)
where the control and compound 1 sample displayed elongated
fibrils among clusters of protofibrils.
In contrast, compounds 5, 6, 7, and 10 appeared to interact
readily with A42 protofibrils as evident by the significant
decrease in ThT signal after adding the compounds to A42
protofibrils at 0 h. TheTEM images of samples containing com-
pounds 5, 6, 7, and 10 were in agreement with the ThT data as
they showed clusters of elongated curvilinear protofibrils (Fig.
5C). Thus, compounds 5, 6, 7, and 10 did not interfere with
the oligomerization of A42 protofibrils but blocked their
fibrillization.
SDS-PAGE analysis was performed to quantify the remain-
ing amount of solubleA42 species (monomers, oligomers, and
protofibrils). The A42 protofibrils generated with our proto-
col were SDS-sensitive, and a band similar tomonomeric A42
was detected at 0 h of incubation (Fig. 5B). A significant
decrease in the amount of soluble A42was observed after 48 h
of incubation for samples containing compounds 1, 5, 6, and
10. Thus, in agreement with the TEM images, compounds 5, 6,
and 10 were not able to disaggregate A42 protofibrils. Inter-
estingly, a larger amount of soluble A42 was detected for sam-
ples containing compound 7 or the control after 48 h of incu-
bation (Fig. 5B) as evident by the A42 band intensity.
Thus, the most plausible mechanism of action for com-
pounds 5, 6, 7, and 10 is an interaction with A42 protofibrils
that results in the formation of clusters of elongated curvilinear
protofibrils with low -sheet content. In addition, compound 7
caused the formation of soluble A42 aggregates similar to
SDS-sensitive A42 protofibrils.
To test the ability of compounds 6, 7, and 10 to disaggregate
amyloid fibrils, they were incubated with preformed mature
A42 fibrils, and the disaggregation was monitored by SDS-
PAGE, TEM, and ThT fluorescence (Fig. 6). The crude A42
preparation already displayed a strong ThT signal at 0 h that
increased considerably over the next 48 h of A42 fibril matu-
ration (Fig. 6D). The addition of DMSO resulted in a slight
FIGURE 4. Inhibition of A42 aggregation kinetics for compounds 1, 5, 6, 7, and 10 (40M) using 10MA42monomers. The total incubation timewas
48 h, after which the samples were analyzed with three different assays: ThT fluorescence (A), SDS-PAGE (B), and TEM (C). The ThT-data are expressed as the
mean S.D.; scale bar for TEM images, 100 nm. a.u., absorbance units.
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decrease of the ThT signal after 24 of incubation, suggesting a
minor interference with the ThT fluorescence. However, the
increase of the ThT signal after 48 h of incubation suggested
that DMSO did not interfere with the reassociation of mature
fibrils. In contrast, samples containing compounds 6, 7, and 10
showed a significant decrease of the ThT signal after 24 and
48 h of incubation, indicating a dissociation of preformedA42
fibrils. The ThT signal for samples containing compounds 6
and 10 after 24 and 48 h of incubation was similar to the initial
crude A42 preparation. In contrast, the ThT signal for sam-
ples containing compound 7 after 24 and 48 h of incubationwas
reduced when compared with the initial crude A42 prepara-
tion (Fig. 6D).
To verify any disaggregation of mature fibrils by DMSO and
compounds 6, 7, and 10, the amount of soluble A42 species
(monomers, oligomers, and protofibrils) after 24 and 48 h of
incubation was determined by SDS-PAGE analysis of the
supernatant (Fig. 6A). Overall, the amount of soluble A42 was
not significantly different between the preformed A42 fibrils
and the samples treated with DMSO or compounds 6, 7, and
10, suggesting that there was no disaggregation of preformed
A42 fibrils. To determine the amount of A42monomers, the
supernatant was additionally filtered and analyzed by SDS-
PAGE (Fig. 6B). In general, the A42 monomer bands were
much weaker in intensity than the corresponding soluble A42
bands (compare Fig. 6,A and B), suggesting that themajority of
soluble A42 species were oligomers and protofibrils. Neither
DMSO nor compounds 6, 7, and 10 increased the amount of
monomeric A42, confirming that compounds 6, 7, and 10 did
not disaggregate preformed A42 fibrils. These findings were
in agreement with the TEM images, where the DMSO sample
aswell as the samples treatedwith compounds 6, 7, and 10 after
48 h of incubation displayed networks of fibrils (Fig. 6C).
Thus, the most plausible mechanism of action for com-
pounds 6, 7, and 10 is an interaction with A42 fibrils that did
not lead to their disaggregation. In addition, compound 7
caused the formation of A42 fibrils with lower -sheet
content.
FIGURE 5. InhibitionofA42aggregationkinetics for compounds1, 5, 6, 7, and10 (40M) using10MA42protofibrils. The total incubation timewas
48 h after which the samples were analyzed with three different assays: ThT fluorescence (A), SDS-PAGE (B), and TEM (C). The ThT data are expressed as the
mean S.D.; scale bar for TEM images, 100 nm. a.u., absorbance units.
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Investigating the InhibitionMechanism of Compounds 5, 6, 7,
and 10 by FCS—Another ThT-independent method for the
assessment of inhibition of A42 aggregation properties of
small molecules is FCS. FCS allows the determination of the
diffusion time of a fluorescent molecule through a small vol-
ume, i.e. the confocal volume of a laser beam of about one fem-
toliter. Protein aggregation causes slower diffusion times, and
highly labeled large aggregates cause large fluorescence bursts
when they pass through the focus (36).
In the case of self-associating molecules, aggregation can be
characterized by the number of fluorescence bursts (Fig. 7A) or
by the product of number and intensity of fluorescence bursts
(Fig. 7B). Unlike ThT-based methods that require the presence
of cross--sheet structures in the protein aggregates to give rise
to a signal, FCS detects any aggregates containing a fluorescent
molecule passing through the detection volume. Very large
aggregates, however, will not be detected as they will deposit
below the confocal volume.
Compounds 5, 6, and 7 reduced the number of small A42
aggregates passing the laser beam by 50% when compared
with conditions with DMSO alone. In contrast, compound 10
did not reduce the number of small A42 aggregates (Fig. 7A).
Taking into account not only the number of A42 aggregates
but also their size (product of peak number and intensity), it
was revealed that compounds 6 and 7 were more potent than
compound 5 in both reducing the number of A42 aggregates
FIGURE 6.Disaggregation of A42 fibrils byDMSO (40M) and compounds 6, 7, and 10 (40M) using 100MA42 fibrils. The incubation time to form
A42 fibrilswas 0h (0hBC) and48hbefore addingDMSOand compounds6,7, and10 (48hBC). Sampleswere then analyzed after 24h (24hAC) and48h (48hAC)
of incubationwith DMSO and compounds 6, 7, and 10 using three different assays: SDS-PAGE (A), SDS-PAGEwith filtration of the supernatant (B), TEM (C), and
ThT fluorescence (D). The ThT data are expressed as the mean S.D. Scale bar for TEM images, 100 nm. a.u., absorbance units.
FIGURE 7.Fluorescence correlation spectroscopyofA42 incubatedwith
compounds 5, 6, 7, and 10. The aggregation of 5 nM A42, N-terminally
labeledwith Oregon green in PBS and 3%DMSO, wasmonitored by FCSwith
or without 200 nM concentrations of compounds 5, 6, 7, and 10. Aggregate
formation was quantified by counting the frequency of intensity spikes
caused by A42 aggregates passing the detection volume (A) and the height
of the intensity spikes (B). Results were normalized to the control aggrega-
tion, and the data are expressed as the mean S.D.
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as well as their size (Fig. 7B). Overall, compound 6 was most
efficient in inhibiting A42 aggregationmonitored by FCS (Fig.
7, A and B).
Investigating the Interaction of Compounds 6, 7, and 10 with
A42 by Nuclear Magnetic Resonance Spectroscopy—NMR
spectroscopy was used to follow the effects of compounds 6, 7,
and 10 on A42. As revealed by the intensity of 1H signals in
one-dimensional NMR spectra, the addition of compound 6
resulted in a considerable loss of signal intensity. The NMR
signal intensity loss showed a clear dependence on the concen-
tration of the compound, resulting in a decrease of up to30%
at a compound/A42 ratio of 30:1 (Fig. 8). The decrease in
intensity was due to the presence of the compound, as the addi-
tion of a reference solution (pure DMSO) did not cause any
significant changes in NMR signal intensities. Very similar
changes in NMR spectra were also observed for compounds 7
(supplemental Fig. S2A) and 10 (supplemental Fig. S2B). Taken
together the observed changes suggest that compounds 6, 7,
and 10 induce formation of large A42 oligomers that are
broadened beyond the detection limit of liquid-state NMR due
to slow tumbling. In addition, separate analysis of backbone and
side chain signals of A42 in the presence of compound 7
showed that the intensity decrease of the methyl groups is
slower, indicating that they remain partially mobile in the olig-
omeric state (supplemental Fig. S2A). In contrast, almost iden-
tical signal decays for methyl and amide signals were observed
for compounds 6 (Fig. 8) and 10 (supplemental Fig. S2B). Thus,
in case of compounds6 and10, the formedA42 oligomers had
either less flexible side chains or had a larger molecular weight.
To obtain residue-specific information about the interaction
of compounds 6, 7, and 10 with A42, two-dimensional
[1H,15N]heteronuclear single quantum coherence spectra (49)
of A42 were measured in the absence and presence of the
compounds. The variation of chemical shifts of amide 1H and
15N spins of A42 upon the addition of the compounds repre-
sented alterations in their chemical environment after direct
binding and/or induced conformational changes. In addition,
the intensity of 1H,15N correlation peaks was affected by the
exchange between the free and bound forms of the peptide and
their intrinsic transverse relaxation rates. Therefore, a com-
bined monitoring of chemical shifts and peak intensities can
provide insights into the thermodynamic and kinetic aspects of
the binding of small molecules to proteins (50). In line with the
observation from one-dimensional 1H NMR spectra, the addi-
tion of compounds 6, 7, and 10 resulted in a decrease in the
intensity of [1H,15N] correlation peaks (supplemental Fig. S3).
The intensity decrease was quite uniform along the sequence
with the exception of residues 25–29, in particular for com-
pounds 7 (supplemental Fig. S3B) and 10 (supplemental Fig.
S3C).
Besides the intensity decrease, a slight perturbation of back-
bone amide chemical shifts was observed (Fig. 9A). In case of
compounds 7 and 10, it was similar both in magnitude and
profile to the deviations observed upon the addition of identical
volumes of pure DMSO. More pronounced chemical shift per-
turbations, however, were observed in the presence of com-
pound 6, especially for residues 10–19 and for many residues
from Ile-31 to Ala-42. With the exception of the basic His-13,
His-14, and Lys-16 residues, all other amino acid residues are
FIGURE 8. Ligand-dependent conversion of A42 into oligomers. Inten-
sity changes of proton signals in one-dimensional 1H NMR spectra of A42
upon the addition of compound 6 at various ratios are shown. Changes in the
methyl and backbone amide signals are shown separately. Reference values
were obtained after the addition of DMSO (without compound 6) at corre-
sponding volumes.
FIGURE 9. A, shown is the interaction of compounds 6, 7, and 10with mono-
meric A42. Shown is the average backbone amide proton and nitrogen
chemical shift deviation obtained from two-dimensional 1H,15N heteronu-
clear single quantum coherence spectra of 15N-labeled A42 in the absence
and presence of the compounds 6, 7, and 10. The compounds 6 and 10 were
present at a compound/peptide ratio of 30:1, whereas the corresponding
value for compound 7was 24:1. Reference datawere obtained after the addi-
tionofDMSO (without compounds) at the corresponding volume.B, shown is
an illustration of the main interactions of compound 6 with hydrophobic
amino acids of monomeric A42 using the NMR structure of A42 fibrils (51)
consisting of five peptides (PDB entry 2BEG).
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hydrophobic. Notably, these residues are located in the regions
of the A42 peptide sequence that constitute the N- and C-ter-
minal -strands of A fibrils (Fig. 9B) (51).
The observed change of chemical shifts in dependence of the
compound 6/A42 ratio was nearly linear, i.e. far from the sat-
uration regime (supplemental Fig. S4). This indicated that the
interaction between monomeric, NMR-observable A42 and
compound 6 was weak with a Kd in the mM range. The NMR
STD technique is a method that allows the detection of inter-
actions between smallmolecules and proteins in awide range of
affinities (KD 108–103 M) (52). In these experiments, an 1H
NMRsignal from the peptide or proteinwas irradiated and kept
saturated for a relatively long time. Then saturation transferred
to all the other protons of the peptide as well as any ligand that
was in contact with the peptide during the saturation period. A
decrease in the 1H NMR signal intensities of the ligand, consti-
tuting the STD signal, represented the binding event. The part
of the small molecule that had the strongest contact/binding
withA42 displays themost intense STD signal. For compound
6 the two peaks at5.8 and 6.0 ppm were well separated from
the A42 peaks and selected for STD analysis (Fig. 10). The two
peaks belong to the protons directly attached to the pyrazole
rings. After the addition of an A42 preparation enriched in
oligomers, the peak at 5.8 ppmwas already broadened in a con-
ventional one-dimensional 1H NMR spectrum, suggesting that
the corresponding proton of compound 6 was involved in the
interaction with A42 (Fig. 10A, upper signals). In line with its
involvement in the interaction with A42, a clear STD signal
was observed at both 5.8 and 6.0 ppm after irradiation at 0.6
ppm that saturates the methyl signals of A42 (Fig. 10A, lower
signals). The aromatic protons from the 4-F-phenyl moieties
(7.0–7.7 ppm) were not separated from the A42 peaks but
also showed clear STD signals after irradiation at 0.6 ppm.
Next we tested the impact of the irradiation frequency on the
STD effect. When the irradiation frequency was moved to1,
2,3, and5 ppm, a continuous decrease of the STD effect
was observed (Fig. 10B). Because no “visible” peptide signal is
located at these up-field frequencies, the STD effects there
should be caused by the “hidden” signals of the oligomeric pep-
tide, which are broadened enough to be “NMR-invisible” but
reach up to frequencies of5 ppm due to severe line broaden-
ing. Therefore, the STD profile confirmed a binding event
between compound 6 and A42 oligomers (Fig. 10B). In line
with a preferential interaction of compound 6 with A42 olig-
omers, the normally solubilized A42 preparation showed
lower STD intensities (gray dots of Fig. 10B). In addition, the
normally solubilized A42 preparation that contains a smaller
amount and potentially different types of oligomers did not
show a STD effect at5 ppm.
Rescue of A42-induced Toxicity and Prevention of A42-
Uptake in Cultured Cells—To study the toxic effect of A42 on
SH-SY5Y cells, we selected a crude A42 preparation contain-
ing mixtures of heterogeneous A42 oligomers and abundant
monomers (20, 39). This preparation was chosen to mimic the
pathological situation in vivo where both monomeric and
protofibrillar A species populate the diseased AD brain. Fur-
thermore, we reported that crude A42 preparations, when
comparedwith purifiedmonomers and protofibrils, weremuch
more toxic to cultured cells including neurons and fibrillized
extensively (20, 45). Compounds 1, 5, 6, 7, and 10 were thus
tested in a cell-based in vitro assay to determine their ability to
increase the viability of SH-SY5Y cells treated with crude A42
as measured by a MTT reduction assay (20). For this assay the
ratio of compound to A42 was 1:1 (10 M) with a 1-h prein-
cubation of the compound with crude A42 followed by a 24-h
treatment of the cells (20). The cell viability assay showed that
compounds 5, 6, 7, and 10 but not compound 1 were able to
reduce the toxicity of crude A42, resulting in increased cell
viability (Fig. 11A).
To better understand the underlying mechanism by which
compounds 5, 6, 7, and 10 increased the cell viability of
SH-SY5Y cells treated with crude A42, we developed anA42
uptake assay (Fig. 11B). The assay is based on the fact that extra-
cellular A42 aggregates have been shown to interact with cel-
lular membranes followed by internalization by endocytosis
resulting in the accumulation of intra-neuronal A42 (53). For
this assay the ratio of compound to A42 was 1:1 (3 M) with a
1-h preincubation of the compound with crude A42 followed
by a 2-h treatment of the SH-SY5Y cells. Internalized A42was
determined using an ELISA for humanA42. Compound 1 had
little effect on crude A42 internalization (10% reduction)
FIGURE 10. Preferential binding of compound 6 to oligomeric A42. STD
spectra of compound 6 in the presence of A42. A, the positive spectra are
one-dimensional (1D) 1H NMR spectra of compound 6 in the absence and
presence of the peptide. The negative spectra are STD spectra obtained at
irradiation frequencies of 0.6,1,2,3, and5 ppm. B, shown is the STD
profile, observed for the ligand peaks at 5.8 and 6.0 ppm as a function of
irradiation frequency. Note that the STD intensities obtained with the
oligomer-enriched preparation of A42 are larger and extend up to5 ppm.
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when compared with conditions without compounds (defined
as 0% reduction), whereas compounds 5, 6, 7, and 10 interfered
with crude A42 internalization (30–60% reduction). Thus,
the improved cell viability of A42-treated SH-SY5Y cells
observed in the presence of compounds 6, 7, and 10 correlated
well with their capability to decrease the cellular uptake of
crude A42 (Fig. 11C).
DISCUSSION
The goal of this study was to rationally design small mole-
cules capable of preventing the formation of toxic A42 spe-
cies. In recent years a number of small molecule inhibitors of
A42 aggregation have been studied. The majority of com-
pounds, mainly natural products, contained phenolic moieties.
Selected examples are apomorphine (18), curcumin (25), ()-
epigallocatechine gallate (32, 33), resveratrol (31), bi- and
mono-flavonoids (54), tannic acid (34), nordihydroguaiaretic
acid (34), tolcapone (45), RS-0466, RS-0406 (55), and O4 (56).
Although all of these compounds have very different chemical
structures, they share common features required for activity
(25, 57). These features are hydroxyl substituents on the aro-
matic moiety, a second terminal aromatic moiety, and a linker
unit to which the aromatic moieties are attached. The optimal
linker length appeared to be between 8 and 16 Å, and the linker
should not contain more than two rotating bonds (25, 57).
For our compoundswe applied a rational design based on the
3-aminopyrazole moiety (35, 36) to retain entropically favor-
able multipoint hydrogen bond interactions with -sheets (36).
The distance between donor and acceptor should be in the
range of 3.5–4.0 Å, and the distance between acceptor and
donor should be 2.6–2.9 Å (35, 58). In this respect, the Ampox
compound (N1,N2-bis(5-methyl-1H-pyrazol-3-yl)oxalamide;
Refs. 35 and 36 and Fig. 1A) represented a suitable lead for
compound optimization whereby the following criteria re-
quired to permeate biological membranes were targeted:
molecular weight 450, polar surface area90 Å2, number of
hydrogen-bond acceptors  7, number of hydrogen-bond
donors  4, and lipophilicity (logarithm of n-octanyl alcohol/
water partition coefficient) 5 (59). Thus, we retained the
3-aminopyrazole ring, incorporated linker units with not more
than two rotating bonds, and added aromatic moieties at each
of the 3-aminopyrazole rings to enable -stacking and/or
hydrophobic interactions with the residues of A42 (Fig. 1).
The use of ThT-based screening assays (Fig. 2) allowed the
rapid screening of our compounds and resulted in the identifi-
cation of compounds 1, 2, 4, 8, 9, 11, 12, and 14with undesired
structural features leading to inferior inhibition of A42 fibril-
lization, i.e. aromatic substituents at the 4-position of the
3-aminopyrazole ring and rigid-linkers. The data fromdifferent
in vitro assays (Fig. 3–10) suggested that the improved activity
in inhibiting A42 fibrillization by compounds 3, 5, 6, 7, 10,
and13was linked to their ability to adopt a conformationwhere
additional -stacking and/or hydrophobic interactions with
A42 were possible. The weak mM binding of compound 6 to
monomeric A42 (supplemental Fig. S4) and the preference of
compound 6 to bind to oligomeric A42 (Fig. 10B) suggested
that the structurally related compounds 3, 5, 7, 10, and 13 bind
preferably to oligomeric A42 species as well.
The preferred interaction of compound 6 with hydrophobic
residues of the N- and C-terminal -strands (Leu-17, Val-18,
Phe-19, Ile-31, Ile-32, Val-36, Val-40, Ile-41, and Ala-42) of
monomeric A42 (Fig. 9) can be directly linked to the presence
of the 3-aminopyrazole ring and the attached aromatic sub-
stituents at the 5-position. The STD spectra (Fig. 10) showed
that at all irradiation frequencies there is an energy transfer
from A42 to compound 6 (Fig. 10A, lower signals), clearly
indicating that both the 3-aminopyrazole ring and the 4-F-phe-
nyl substituent have direct binding contacts with these A42
residues. A similarmode of interactionwas proposed earlier for
the recognition of the hexapeptide sequence (KKLVFF) of res-
idues 15–20 of A42 by a trimeric 3-aminopyrazole ligand (36).
FIGURE 11. Inhibition of crude A42 induced toxicity and inhibition of internalization of crude A42 by compounds 1, 5, 6, 7, and 10monitoredwith
SH-SY5Y neuroblastoma cells. A, assessment of crude A42 toxicity in the presence of compounds 1, 5, 6, 7, and 10 by employing a MTT reduction assay is
shown. Crude A42 was preincubated for 1 h with the compounds a 1:1 molar ratio (10 M) before the cells were treated with the mixture for 24 h. B, shown
is an assessment of the efficacy of compounds 1, 5, 6, 7, and 10 to prevent crude A42 internalization into SH-SY5Y cells. Crude A42was preincubated for 1 h
with the compounds at a 1:1 molar ratio (3 M) before the cells were treated with the mixture for 2 h. C, shown is correlation between inhibition of internal-
ization of crude A42 and inhibition of crude A42-induced toxicity by compounds 1, 5, 6, 7, and 10. The data are expressed as the mean  S.D. of three
independent experiments.
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The polyphenolic compound O4 preferably targets the hydro-
phobic residues 17–20 and 31–37 of A40 as well (56). The
importance of-stacking and/or hydrophobic interactions was
also observed in the preferred binding of phthalocyanine tetra-
sulfate to the heptapeptide sequence (EGVLYVG) of residues
35–41 of -synuclein (50).
The suppression of the rise of the ThT-signal in kinetic
experiments using A42 monomers (Fig. 4A) and A42 proto-
fibrils (Fig. 5A) provide further evidence that compounds 5, 6,
7, and 10 interact with the -sheets already present in oligo-
meric A42. Infrared spectroscopy and x-ray diffraction have
demonstrated the presence of significant amounts of -sheet
structure in A42 protofibrils and fibrillar oligomers (60–62)
that appear as the earliest fibrillar aggregates within the A
amyloidogenic pathway (47) and are putatively a major cyto-
toxic A species (63). It was already demonstrated that ThT
recognizes prefibrillar A aggregates (64) and that the ThT
fluorescencewas onlymodestly increased (1.5-fold) when com-
pared with fibrils (100-fold). The lower ThT fluorescence of
prefibrillar or oligomeric A aggregates can be explained by the
lower -sheet content of oligomers (48–57%) when com-
pared with fibrils (61).
Previous studies with small molecule inhibitors of A42
aggregation allowed the differentiation of active compounds
into three subsets (34, 46). Class I (e.g. Congo red, curcumin,
nordihydroguaiaretic acid) inhibited A42 oligomerization but
not A42 fibril formation. Class II (e.g.methylene blue, rhoda-
mine B, phenol red) inhibited both A42 oligomerization and
A42 fibril formation. Class III (e.g. orange G, piceid, tannic
acid) inhibited A42 fibril formation but not A42 oligomeri-
zation (34, 46). Regarding the fibrillization of A42 monomers
and protofibrils, compounds 5, 6, 7, and 10 seemed to display
the behavior of class III compounds and acted by kinetic stabi-
lization of A42 oligomeric intermediates (Figs. 4 and 5). In
addition, compound 7 also increased the amount of soluble
A42 aggregates similar to SDS sensitiveA42 protofibrils (Fig.
5B). Unlike class III compounds reported in literature (34),
compounds 5, 6, 7, and 10 were not able to disaggregate pre-
formed A42 fibrils (Fig. 6) into low molecular weight species.
Again compound 7 displayed a somewhat different behavior by
inducing the formation of A42 fibrils with reduced ThT bind-
ing capacity (Fig. 6D).
FCS data revealed a reduction of the number of small A42
aggregates for compounds 5, 6, and 7 but not compound 10
(Fig. 7A). The FCS data for larger A42 aggregates (Fig. 7B)
matched compound 6 when A42 monomers were used, lead-
ing to an increased amount of soluble A42 (Fig. 4B). For com-
pound 7, however, the use of A42 protofibrils resulted in the
formation of A42 aggregates that were indistinguishable from
SDS-sensitive A42 protofibrils (Fig. 5B). Thus, we speculate
that the A42 aggregates detected by FCS are different in size
and conformation.
Compounds 6, 7, and 10 most efficiently increased the via-
bility of cells treated with toxic A42 (Fig. 11A) and decreased
the cellular uptake of A42 (Fig. 11B). NMR experiments
showed an interaction between compound 6 and the two adja-
cent histidines at positions 13 and 14 of monomeric A42 (Fig.
9A). Both residues are important forA42 cellmembrane bind-
ing and uptake (65). One possible mechanism for A42 oligo-
mer toxicity is related to their interaction with lipid bilayers in
which they might cause perturbation and/or permeabilization
(18, 66). An earlier study using human neuroblastoma cells
showed that oligomeric A42 was internalized more efficiently
than fibrillar A42 (67).We speculate that a similar interaction
of compounds 6, 7, and 10 with oligomeric A42 may in part
explain their rescuing effect. Despite being a potent compound
in the ThT IC50 and kinetic of A42 monomer and protofibril
fibrillization assays, compound 5 displayed a weaker rescuing
capacity. This may be related to the relatively high degree of
A42 internalization found in the presence of compound 5
(Fig. 11B). This indicates that subtle differences between small
molecule inhibitors of A42 fibrillization (electron-deficient
4-F-phenyl substituent for compound 6; electron-rich substit-
uent (4-(CH3)2N-phenyl for compound 7; electron-rich sub-
stituents 4-tolyl/2-thiophenyl for compound 10; electron-defi-
cient 4-Cl-phenyl substituent for compound 5) can lead to
different mechanistic interactions with A42 species, resulting
in a different reduction of A42mediated toxicity. A reduction
of A42 toxicity in vitro was also observed for curcumin (68),
()-epigallocatechine gallate (32), resveratrol (69), RS-0406
(55, 70), and O4 (56), which have different interactions with
A42 as well. Furthermore, attenuation of A42 toxicity was
also observed when the kinetic stabilization of A42 protofi-
brils was enhanced by adding A40 monomers (23), and inter-
estingly, small molecules stabilizing A42 protofibrils in vitro
improved behavioral performance in APP-transgenic mice
(71).
In summary, compounds 6, 7, and 10 showed the validity of
our inhibitor design (flexible (-CH2-CH2-) linker unit and aro-
matic substituents at the 5-position of 3-aminopyrazole) to tar-
get hydrophobic residues of A42. Compounds 6, 7, and 10
efficiently prevented pathological self-assembly ofA42mono-
mers and A42 protofibrils by binding to oligomeric A42,
broke down neurotoxic A42 oligomers, increased the viability
of SH-SY5Y neuroblastoma cells when challenged with toxic
crude A42 mixture, and decreased cellular uptake of A42.
Thus, compounds 6, 7, and 10 have potential as novel drug
candidates for the treatment of neurodegeneration in AD and
related amyloid diseases.
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